2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
3.063
-0.048 (-1.52%)
Nov 21, 2024, 11:42 AM EST - Market open
2seventy bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 10.4, with a low estimate of 5.00 and a high estimate of 18. The average target predicts an increase of 239.59% from the current stock price of 3.06.
Analyst Consensus: Buy
* Price targets were last updated on Jul 29, 2024.
Analyst Ratings
The average analyst rating for 2seventy bio stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +95.92% | Jul 29, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +63.27% | Jun 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +259.18% | May 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +291.84% | Apr 8, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +63.27% | Mar 18, 2024 |
Financial Forecast
Revenue This Year
56.00M
from 100.39M
Decreased by -44.22%
Revenue Next Year
73.90M
from 56.00M
Increased by 31.98%
EPS This Year
-0.96
from -4.42
EPS Next Year
-0.44
from -0.96
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 78.1M | 106.2M | 118.1M | ||
| Avg | 56.0M | 73.9M | 99.0M | ||
| Low | 40.2M | 46.4M | 80.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -22.2% | 89.7% | 59.8% | ||
| Avg | -44.2% | 32.0% | 34.0% | ||
| Low | -60.0% | -17.2% | 8.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.62 | 0.42 | 0.65 | |
| Avg | -0.96 | -0.44 | -0.03 | |
| Low | -1.20 | -0.97 | -0.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.